Which dose of vandetanib works best for thyroid cancer?

NCT ID NCT01496313

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two daily doses (150mg vs 300mg) of the drug vandetanib in 81 adults with advanced medullary thyroid cancer that had spread or caused symptoms. The goal was to see which dose better shrinks tumors and how side effects compare. Patients took the drug for up to 24 months, with dose reductions allowed for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vandetanib
What this could lead to: If successful, this could help doctors choose the best dose of vandetanib to control advanced medullary thyroid cancer with fewer side effects.
What could go wrong: This is a small, completed Phase 4 study, so results may not apply to all patients. Vandetanib can cause serious side effects like heart problems and diarrhea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Medullary familial medullary thyroid carcinoma Neoplasm Metastasis thyroid cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID CANCER

Contacts and locations

Locations

Investigational Site Number : 1901

Prague, 15006, Czechia
Investigational Site Number : 1903

Olomouc, 77900, Czechia
Investigational Site Number : 5703

Gliwice, 44-101, Poland
Investigational Site Number : 5704

Warsaw, Masovian Voivodeship, 02-781, Poland
Research Site

Houston, Texas, United States
Research Site

Olomouc, Czechia
Research Site

Prague, Czechia
Research Site

Bangalore Karnataka, India
Research Site

Vellore, India
Research Site

Beersheba, Israel
Research Site

Haifa, Israel
Research Site

Jerusalem, Israel
Research Site

Petah Tikva, Israel
Research Site

Catania, Italy
Research Site

Milan, Italy
Research Site

Palermo, Italy
Research Site

Pisa, Italy
Research Site

Roma, Italy
Research Site

Siena, Italy
Research Site

Torino, Italy
Research Site

Groningen, Netherlands
Research Site

Leiden, Netherlands
Research Site

Gliwice, Poland
Research Site

Warsaw, Poland
Research Site

Zgierz, Poland
Research Site

Saint Petersburg, Russia
Research Site

Cardiff, United Kingdom
Research Site

Greater London, United Kingdom
Research Site

London, United Kingdom
Research Site

Tyne & Wear, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.